23andme Holding Co (ME) - News Archive

In a pivotal announcement, Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, publicized, through an amendment to her Schedule 13D, her intent to take the company private...

The Phase 1 clinical trial will involve the evaluation of 23ME-01473 in individuals with advanced solid tumors. This initial stage of trials is crucial in determining the safety and tolerability of the antibody in human...

23andMe Launches New Genetic Reports on Common Forms of Cancer23andMe, the leading direct-to-consumer genetic testing company, has taken a major step forward in personalized healthcare with the launch of new genetic rep...

Recent announcements from genetics and biotechnology company 23andMe have highlighted their participation in the American Association for Cancer Research (AACR) Annual Meeting 2024. The company s presentations on their...

hereby acknowledges the recent achievement of 23andMe Holding Co., a front-runner in the realm of human genetics and biopharmaceuticals. The company has successfully procured clearance from the U.S. Food and Drug Admini...

23andMe is Stepping Up its Targeted Cancer Therapies Despite Falling Revenue The genetic testing and research company 23andMe, is expanding its Phase 1/2a clinical trial, 23ME-00610, by enrolling 30 additional patients...